Amarin Presents New Clinical Data Evaluating Lipoprotein(A) And Other apoB Containing Lipoproteins As Predictors Of MACE, At AHA Scientific Sessions 2026

Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical data evaluating lipoprotein(a) [Lp(a)] and other apolipoprotein B (apoB) containing lipoproteins as predictors of major adverse cardiovascular events (MACE), as well as new mechanistic findings examining the effects of eicosapentaenoic acid (EPA) on Lp(a) oxidation and related inflammatory and oxidative stress pathways. The data were presented at the American Heart Association (AHA) Scientific Sessions 2026 this weekend in Chicago, Illinois.

The new research comes amid increased scientific focus on Lp(a) as an important contributor to residual cardiovascular risk and builds on previously published findings from the REDUCE-IT® Lp(a) post hoc analysis published in the Journal of the American College of Cardiology (JACC).i That analysis demonstrated that baseline Lp(a) levels were associated with increased cardiovascular risk despite statin-controlled LDL-C, while icosapent ethyl (IPE) consistently reduced MACE on top of statin therapy across the spectrum of Lp(a) concentrations, including among patients with clinically relevant elevations in Lp(a). Importantly, these findings remain highly relevant following the recent announcement that the Lp(a)HORIZON cardiovascular outcomes trial did not meet its primary endpoint despite substantial Lp(a) lowering, highlighting the need for therapies that have demonstrated cardiovascular event reduction in high-risk patients.ii VASCEPA/VAZKEPA (icosapent ethyl) is approved and commercially available in major global regions and has demonstrated cardiovascular benefit on top of statin therapy in REDUCE-IT participants with both high and low baseline Lp(a) levels.